Analysis of Interleukin 18 during therapy with glatiramer acetate (Copaxone) in patients with relapsing-remitting multiple sclerosis

Folia Neuropathologica

Volumn 39, Issue SUPPL. A, 2001, Pages 23-24

  Losy, Jacek ^a   Michałowska Wender, Grazyna ^a   Wender, Mieczysław ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Glatiramer acetate; IL 18; Multiple sclerosis

Indexed keywords

EID: 0012914470     PISSN: 00283894     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Arnason B (1995) The role of cytokines in multiple sclerosis. Neurology, 45: 54-55.
2. Bansil C, Cook S, Rohowsky-Kockaz C (1995) Multiple sclerosis immune mechanism and update on current therapies. Ann Neurol, 37: 87-101.
3. Gran B, Tranquill L, Chen M, Bielekowa B, Zhou W, Dhib-Jalbut S, Martin R (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology, 55: 1704-1714.
4. Jander S, Stoll G (1998) Differential induction of interleukin-12, interleukin 18, and interleukin-1 beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. J Neuroimmunol, 91: 93-99.
5. Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky J (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis, 6: 255-266.
6. Losy J, Niezgoda A (2001) IL-18 in patients with multiple sclerosis. Acta Neurol Scand, 104: 171-173.
7. Miller A, Shapiro S, Geshtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N (1998) Treatment of multiple sclerosis with Copolymer-1 (Copaxone): implicating mechanisms of Th-1 to Th-2/Th-3 immune-deviation. J Neuroimmunol, 92: 113-121.
8. Poser C, Paty D, Scheinberg L (1983) New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol, 13: 227-231.
9. Son Y, Dallal R, Mailliard R, Egawa S, Jonak Z, Lotze M (2001) Interleukin-18 (IL-18) synergizes of natural killer cells. Cancer Res, 61: 884-888.